Farxiga is not a semaglutide. These are two completely different medications that belong to separate drug classes and work through distinct mechanisms in the body. Farxiga (dapagliflozin) is an SGLT-2 inhibitor, while semaglutide is a GLP-1 receptor agonist sold under brand names like Ozempic, Wegovy, and Rybelsus. Both can lower blood sugar in people with type 2 diabetes, which is likely why they get confused, but they do so in fundamentally different ways.
How Farxiga Works
Farxiga belongs to a class of drugs called SGLT-2 inhibitors. These work in your kidneys rather than your gut or brain. Normally, your kidneys filter glucose out of your blood and then reabsorb most of it back into your bloodstream. Farxiga blocks that reabsorption process, causing excess glucose to leave your body through urine. The result is lower blood sugar levels without directly affecting insulin production.
This kidney-based mechanism gives Farxiga a unique set of benefits beyond blood sugar control. The FDA has approved it for four distinct uses: improving blood sugar in adults with type 2 diabetes, reducing the risk of hospitalization for heart failure, protecting kidney function in people with chronic kidney disease at risk of progression, and lowering cardiovascular risk in people with type 2 diabetes who have established heart disease or multiple risk factors. Farxiga is taken as a daily oral tablet.
How Semaglutide Works
Semaglutide mimics a natural gut hormone called GLP-1 that your body releases after eating. This hormone triggers insulin release from your pancreas when blood sugar is elevated, slows down how quickly food leaves your stomach, and signals fullness to areas of your brain that regulate hunger and appetite. By copying all of these effects, semaglutide lowers blood sugar and significantly reduces how much you eat.
That appetite suppression is a major differentiator. It’s why semaglutide has become widely known for weight loss under the brand name Wegovy, which is FDA-approved to reduce excess body weight in adults and adolescents aged 12 and older with obesity, and in adults with overweight who have at least one weight-related health condition. Wegovy also carries an approval to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with established heart disease and obesity or overweight. The SELECT trial found that semaglutide reduced the rate of these events by 20% compared to placebo in this population. Semaglutide is available as a once-weekly injection (Ozempic for diabetes, Wegovy for weight management) or as a daily oral tablet (Rybelsus for diabetes).
Key Differences at a Glance
- Drug class: Farxiga is an SGLT-2 inhibitor; semaglutide is a GLP-1 receptor agonist.
- Where it acts: Farxiga works in the kidneys to flush out excess sugar. Semaglutide works through the pancreas, stomach, and brain to boost insulin, slow digestion, and reduce appetite.
- Weight loss: Farxiga produces modest weight loss, typically a few pounds, as a secondary effect of excreting glucose. Semaglutide produces substantially more weight loss due to its direct effect on appetite and is specifically approved for weight management at higher doses.
- How you take it: Farxiga is a once-daily pill. Semaglutide comes as a once-weekly injection or a daily pill depending on the brand.
- Kidney protection: Farxiga has a specific FDA approval for slowing chronic kidney disease progression, which semaglutide does not.
- Heart failure: Farxiga is approved to reduce heart failure hospitalization across a broad heart failure population. Semaglutide’s cardiovascular benefit is focused on reducing heart attacks and strokes in people with obesity or overweight and existing heart disease.
Side Effects Differ Too
Because these drugs work in completely different parts of the body, their side effect profiles barely overlap. Farxiga’s most notable risks stem from its kidney mechanism: increased urination, genital yeast infections, and urinary tract infections are common. A rarer but serious concern is a type of diabetic ketoacidosis that can occur even when blood sugar isn’t particularly high.
Semaglutide’s side effects are primarily gastrointestinal. Nausea is the most common complaint, especially during the dose-escalation period when you’re gradually increasing your dose over several weeks. Vomiting, diarrhea, and constipation are also frequently reported. These symptoms tend to improve over time for most people, but they can be significant enough that some discontinue treatment.
Can You Take Both Together?
Yes. Farxiga and semaglutide have no known drug interactions and are sometimes prescribed together, particularly for people with type 2 diabetes who need additional blood sugar control or who have both cardiac and metabolic risk factors. Because the two drugs lower blood sugar through entirely separate pathways, combining them can provide complementary benefits: semaglutide addressing appetite and insulin secretion while Farxiga removes excess glucose through the kidneys and provides kidney and heart failure protection. Your prescriber would monitor you for low blood sugar if you’re also taking insulin or certain other diabetes medications, but the SGLT-2 and GLP-1 combination itself does not carry a duplication warning.